title: Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study.
abstract: OBJECTIVE
  To assess the safety of AT-1015 in combination with high-dose aspirin (300 mg daily). Study subjects were 17 healthy male volunteers.
  
  
  METHODS
  This was an open-label, single-center study. Subjects received aspirin 300 mg once daily, alone on days 1-4, and together with AT-1015 40 mg twice daily on days 5-11. A follow-up assessment was performed on day 18. The primary outcome measure was bleeding time; secondary outcome measures were vital signs, adverse events, physical examinations, 12-lead electrocardiograms (ECG) and laboratory safety tests.
  
  
  RESULTS
  There was a significant increase in bleeding time between screening and the end of the aspirin-only period (mean bleeding time 4.8 vs 7.6 min, p = 0.01), but there were no further significant increases during the combination treatment period. The most common adverse events were dry mouth, epistaxis, gingival bleeding and abdominal pain. All treatment-related adverse events were mild in severity and no major bleeding episodes occurred. There were no clinically significant changes in vital signs, physical examinations, 12-lead ECGs or laboratory safety tests.
  
  
  CONCLUSIONS
  AT-1015 was safe and well-tolerated in healthy male volunteers when taken in combination with high-dose aspirin, and did not significantly prolong bleeding time compared with aspirin alone.
authors.affiliation: Ajinomoto Pharmaceuticals Europe Limited, Redhill, Surrey, UK.
authors.forename: D
authors.initials: D
authors.lastname: Anderson
authors.forename: N
authors.initials: N
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Onomichi
authors.forename: H
authors.initials: H
authors.lastname: Uchida
authors.forename: S
authors.initials: S
authors.lastname: Shelley
authors.forename: D
authors.initials: D
authors.lastname: Engert
authors.forename: J
authors.initials: J
authors.lastname: Ilgenfritz
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D001760:Bleeding Time; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D010975:Platelet Aggregation Inhibitors; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; D001241:Aspirin